Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
J Addict Med
; 15(3): 187-190, 2021.
Article
em En
| MEDLINE
| ID: mdl-32909986
ABSTRACT
BACKGROUND:
It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).METHODS:
Retrospective review of patients (Nâ=â31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.RESULTS:
No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx. DISCUSSION ANDCONCLUSIONS:
With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV. SCIENTIFICSIGNIFICANCE:
This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Buprenorfina
/
Hepatite A
/
Transtornos Relacionados ao Uso de Opioides
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article